Table 4 Post-index healthcare utilization among patients with 12 months of continuous enrollment post-index
All Patients | Pirfenidone | Nintedanib | P Value1 | |
|---|---|---|---|---|
N = 614 | N = 348 | N = 266 | ||
All-cause utilization | ||||
Inpatient hospitalization2, n (%) | 156 (25.4) | 91 (26.1) | 65 (24.4) | 0.629 |
Length of stay, mean (SD), days | 4.4 (3.7) | 4.2 (3.5) | 4.8 (4.1) | 0.263 |
Median | 3 | 3 | 3.5 | |
Any outpatient visit, n (%) | 610 (99.1) | 346 (99.4) | 264 (99.2) | 1.000 |
Emergency department visit | 206 (33.6) | 112 (32.2) | 94 (35.3) | 0.412 |
Physician office visit | 600 (97.7) | 340 (97.7) | 260 (97.7) | 0.972 |
Pharmacy, n (%) | 614 (100.0) | 348 (100.0) | 266 (100.0) | 1.000 |
Medication claims PPPY, mean (SD) | 49.6 (27.0) | 49.7 (26.4) | 49.5 (27.8) | 0.938 |
Respiratory-related utilization | ||||
Inpatient hospitalization2, n (%) | 70 (11.4) | 45 (12.9) | 25 (9.4) | 0.172 |
Length of stay, mean (SD), days | 4.9 (4.1) | 4.1 (2.9) | 6.3 (5.4) | 0.033 |
Median | 4 | 3.5 | 4 | |
Any outpatient visit, n (%) | 607 (98.9) | 343 (98.6) | 264 (99.2) | 0.705 |
Emergency department visit | 116 (18.9) | 64 (18.4) | 52 (19.5) | 0.716 |
Physician office visit | 597 (97.2) | 338 (97.1) | 259 (97.4) | 0.856 |
Pharmacy, n (%) | 614 (100.0) | 348 (100.0) | 266 (100.0) | 1.000 |
Medication claims PPPY, mean (SD) | 14.6 (8.0) | 14.4 (7.5) | 14.8 (8.6) | 0.517 |